Genetic determinants of drug-induced agranulocytosis: Potential risk of olanzapine?

Pharmacopsychiatry

Volumn 32, Issue 3, 1999, Pages 110-112

  Dettling, M ^b   Cascorbi, I ^a   Hellweg, R ^c   Deicke, U ^c   Weise, L ^c   Muller Oerlinghausen B ^c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMITRIPTYLINE; FLUPENTIXOL; HALOPERIDOL; OLANZAPINE; PERAZINE; PIMOZIDE; RISPERIDONE;

ADULT; AGRANULOCYTOSIS; ARTICLE; CASE REPORT; CAUCASIAN; DRUG INDUCED DISEASE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENETIC RISK; GERMANY; HLA TYPING; HUMAN; HYPONATREMIA; JEW; LIVER TOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0032839433     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979204     Document Type: Article

References (7)

1. 1 Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B: Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA-subtyping in a Caucasian sample. (submitted) 1999
2. 2 Inman WH: Blood disorders and suicide in patients taking mianserin or amitriptyline. Lancet 1988; 2: 90-92
3. 3 Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis, EJ: HLA-B38, DR4, DQOw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch. Gen. Psychiatry 1990; 47: 945-948
4. 4 Nemeroff CB: Dosing the antipsychotic olanzapine. J. Clin. Psychiatry 1997; 58 (Suppl. 10): 45-49
5. 5 Uetrecht JP: Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes. Pharm. Res. 1989; 6: 265-273
6. 6 Wray CM, Stzuke-Fournier A: Olanzapine: hematological reactions. Can. Med Assoc. J. 1998; 159: 81-82, 85-86
7. 7 Yunis JJ, Corzo M, Salazar M, Lieberman JA, Howard A, Yunis EJ: HLA-associations in clozapine-induced agranulocytosis. Blood 1995; 86: 1177-1183